Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases

2020 ◽  
Vol 41 (4) ◽  
pp. 327-335
Author(s):  
Omnia Mohamed Talaat ◽  
Ismail Mohamed Ali ◽  
Sherif Maher Abolyazid ◽  
Bader Abdelmaksoud ◽  
Ibrahim Mansour Nasr
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Differentiated Thyroid Cancer

scholarly journals Management of differentiated thyroid cancer diagnosed during pregnancy

1999 ◽  
pp. 404-406 ◽  
Author(s):  
L Vini ◽  
S Hyer ◽  
B Pratt ◽  
C Harmer
Keyword(s):  
Thyroid Cancer ◽  
Bone Metastases ◽  
Differentiated Thyroid Cancer ◽  
Subtotal Thyroidectomy ◽  
Second Trimester ◽  
Original Cohort ◽  
Well Differentiated ◽  
Disease Free ◽  
In Pregnancy

OBJECTIVE: To assess the outcome of thyroid cancer diagnosed during pregnancy. DESIGN: Retrospective analysis of patients diagnosed between 1949 and 1997 with thyroid cancer presenting during pregnancy. RESULTS: Nine women with a median age of 28 years were identified. A thyroid nodule was discovered by the clinician during routine antenatal examination in four cases, the remainder had noted a lump in the neck. In all patients, the nodule was reported to almost double in size during the pregnancy. One patient underwent subtotal thyroidectomy during the second trimester; eight were operated on within 3 to 10 months from delivery. Total thyroidectomy was performed in five and subtotal thyroidectomy in four. All tumours were well differentiated and ranged in size from 1 to 6 cm. OUTCOME: The median follow-up was 14 years (5-31 years). One patient relapsed locally requiring further surgery. One patient developed bone metastases dying 7 years after presentation; her planned treatment had been delayed because of an intervening pregnancy. Eight of the original cohort of patients are currently disease free. CONCLUSIONS: Differentiated thyroid cancer presenting in pregnancy generally has an excellent prognosis. When the disease is discovered early in pregnancy, surgery should be considered in the second trimester but radioiodine scans and treatment can be safely delayed until after delivery. In all cases, treatment should not be delayed for more than a year.

Long-Term Follow-Up of Patients With Differentiated Thyroid Cancer Who had Negative 131I Whole-Body Scan at First Evaluation After Treatment

2013 ◽  
Vol 38 (10) ◽  
pp. 765-769 ◽  
Author(s):  
Luciana Souza Cruz Caminha ◽  
Denise Prado Momesso ◽  
Fernanda Vaisman ◽  
Rossana Corbo ◽  
Mario Vaisman
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Whole Body ◽  
Whole Body Scan ◽  
Body Scan ◽  
Long Term Follow Up

scholarly journals Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3282
Author(s):  
Dana M. Hartl ◽  
Joanne Guerlain ◽  
Ingrid Breuskin ◽  
Julien Hadoux ◽  
Eric Baudin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Postoperative Morbidity ◽  
Intermediate Risk ◽  
Thyroid Lobectomy ◽  
Pros And Cons ◽  
Short And Long Term ◽  
Extensive Surgery

Many recent publications and guidelines have promoted a “more is less” approach in terms of treatment for low to intermediate risk differentiated thyroid cancer (DTC), which comprise the vast majority of thyroid cancers: less extensive surgery, less radioactive iodine, less or no thyroid hormone suppression, and less frequent or stringent follow-up. Following this approach, thyroid lobectomy has been proposed as a means of decreasing short- and long-term postoperative morbidity while maintaining an excellent prognosis for tumors meeting specific macroscopic and microscopic criteria. This article will examine the pros and cons of thyroid lobectomy for low to intermediate risk cancers and discuss, in detail, criteria for patient selection and oncological outcomes.

Survey on Paediatric Differentiated Thyroid Cancer Care in Europe

2017 ◽  
Vol 89 (1) ◽  
pp. 58-62 ◽  
Author(s):  
Bernadette L. Dekker ◽  
Kate L. Newbold ◽  
Dagmar Führer ◽  
Steven G. Waguespack ◽  
Daria Handkiewicz-Junak ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
European Countries ◽  
Research Network ◽  
European Network ◽  
Cancer Research Network ◽  
Organization Of Care ◽  
Long Term Consequences

Background/Aims: Thyroid cancer among children is a very rare disease. Although survival is favourable, morbidity caused by the treatment remains considerable, so there is a great need to optimize management by international cooperation. For this reason, the 2016 European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Copenhagen, Denmark, paid considerable attention to this topic and aimed to give an overview of the care for this paediatric patient group in different European countries. Methods: An inventory of data on thyroid cancer treatment among children in Europe was generated by questionnaires focused on treatment and organization of care. Results: The treatment of paediatric thyroid cancer appears to be scattered in each European country with limited centralization of care, and different European countries use different treatment and follow-up protocols. Conclusion: Collaboration in a European network to optimize treatment and minimize long-term consequences for paediatric thyroid cancer survivors is necessary. During this meeting, the ETA-CRN has endorsed the initiative to collaborate on this rare endocrine cancer within a European network.

scholarly journals Differentiated Thyroid Cancer with Biochemical Incomplete Response: Clinico-Pathological Characteristics and Long Term Disease Outcomes

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5422
Author(s):  
Miriam Steinschneider ◽  
Jacob Pitaro ◽  
Shlomit Koren ◽  
Yuval Mizrakli ◽  
Carlos Benbassat ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Staging System ◽  
Response To Therapy ◽  
American Thyroid Association ◽  
Incomplete Response ◽  
Structural Disease ◽  
Stratification System

Although most patients with differentiated thyroid cancer (DTC) and biochemical incomplete response (BIR) follow a good clinical outcome, progression to structural disease may occur in 8–17% of patients. We aimed to identify factors that could predict the long-term outcomes of BIR patients. To this end, we conducted a retrospective review study of 1049 charts from our Differential Thyroid Cancer registry of patients who were initially treated with total thyroidectomy between 1962 and 2019. BIR was defined as suppressed thyroglobulin (Tg) > 1 ng/mL, stimulated Tg > 10 ng/mL or rising anti-Tg antibodies, who did not have structural evidence of disease, and who were assessed 12–24 months after initial treatment. We found 83 patients (7.9%) matching the definition of BIR. During a mean follow-up of 12 ± 6.6 years, 49 (59%) patients remained in a state of BIR or reverted to no evidence of disease, while 34 (41%) progressed to structural disease. At the last follow-up, three cases (3.6%) were recorded as disease-related death. The American Thyroid Association (ATA) Initial Risk Stratification system and/or AJCC/TNM (8th ed.) staging system at diagnosis predicted the shift from BIR to structural disease, irrespective of their postoperative Tg levels. We conclude that albeit 41% of BIR patients may shift to structural disease, and most have a rather indolent disease. Specific new individual data enable the Response to Therapy reclassification to become a dynamic system to allow for the better management of BIR patients in the long term.

scholarly journals Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4338
Author(s):  
Michele Klain ◽  
Emilia Zampella ◽  
Leandra Piscopo ◽  
Fabio Volpe ◽  
Mariarosaria Manganelli ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
High Risk ◽  
Differentiated Thyroid Cancer ◽  
Response To Therapy ◽  
Whole Body ◽  
American Thyroid Association ◽  
Neck Ultrasound ◽  
Risk Of Recurrence

This study assessed the long-term predictive value of the response to therapy, evaluated by serum thyroglobulin (Tg) determination and neck ultrasound, and estimated the potential additional impact of diagnostic whole-body scan (WBS) in patients with differentiated thyroid cancer (DTC) treated with surgery and radioactive iodine (RAI) therapy. We retrospectively evaluated 606 DTC patients treated with surgery and RAI. Response to 131I therapy at 12 months was assessed by serum Tg measurement, neck ultrasound, and diagnostic WBS. According to American Thyroid Association (ATA) guidelines, patients were classified as having a low, intermediate or high risk of recurrence and at 12 months as having an excellent response (ER) or no-ER. Follow-up was then performed every 6–12 months with serum Tg determination and imaging procedures. With a median follow-up of 105 months (range 10–384), 42 (7%) events requiring further treatments occurred. Twenty-five patients had additional RAI therapy, 11 with structural disease in the thyroid bed, eight in both thyroid bed and neck lymph nodes, four had lung metastases and two had bone metastases. The other 17 patients had additional surgery for nodal disease followed by RAI therapy. The ATA intermediate and high risk of recurrence, post-operative and pre-RAI therapy Tg ≥ 10 ng/mL, and the absence of ER at 12 months were independent predictors of events. Diagnostic WBS at 12 months permitted the identification of only five recurrences among the 219 ER patients according to serum Tg levels and ultrasound. In DTC patients, the response to therapy at 12 months after RAI therapy could rely on serum Tg measurement and neck ultrasound, while diagnostic WBS was not routinely indicated in patients considered in ER.

scholarly journals Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer

2015 ◽  
Vol 173 (6) ◽  
pp. 873-881 ◽  
Author(s):  
Daria Handkiewicz-Junak ◽  
Tomasz Gawlik ◽  
Jozef Rozkosz ◽  
Zbigniew Puch ◽  
Barbara Michalik ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Clinical Investigation ◽  
Medical Intervention ◽  
Radioiodine Treatment ◽  
Recombinant Human Thyrotropin ◽  
Almost All ◽  
Tsh Stimulation

AimAlthough recombinant human thyrotropin (rhTSH) is widely used in treating differentiated thyroid cancer (DTC), almost all clinical investigation has been in adults. The aim of our retrospective study was to evaluate outcomes of adjuvant, rhTSH-aided radioiodine treatment in children/adolescents with DTC and to compare them to131I therapy duringl-thyroxin withdrawal (THW).MethodsPatients with the diagnosis of DTC who were ≤18 years of age and had no signs of persistent disease at the time of131I treatment were included; 48 patients were treated after rhTSH (rhTSH group) and 82 after THW group. The median time of follow-up after therapy was 67 months and was longer in the THW group (99 vs 43 months,P<0.05).ResultsOn the day of131I administration, all but one patient had TSH levels above 25 μIU/ml. Peak TSH concentration was significantly higher in the rhTSH group (152 μIU/ml vs 91 μIU/ml). Similarly, the thyroglobulin concentration was higher in the rhTSH group (9.7 ng/ml vs 1.8 ng/ml). No side effects requiring medical intervention were recorded after rhTSH administration. The evaluation of disease outcomes during TSH stimulation (6–18 months after131I treatment) revealed equal rates of thyroid ablation (71%) in both groups. During subsequent follow-up, five patients showed recurrence (P>0.05).ConclusionsIn children/adolescents, rhTSH-aided adjuvant radioiodine treatment is associated with rates of remnant ablation and short-term recurrence similar to THW. As this preparation has several advantages over THW, rhTSH may become the preferred method of TSH stimulation once studies of long-term outcomes show non-inferiority to THW in this age group.

scholarly journals Assessing the influence of special treatment of differentiated thyroid cancer on the urinary system long-term effects

2021 ◽  
Vol 29 (3) ◽  
pp. 22-30
Author(s):  
L.Ya. Vasyliev ◽  
Ye.B. Radzishevska ◽  
A.S. Savchenko ◽  
H.V. Kulinich ◽  
O.O. Solodovnikova
Keyword(s):  
Thyroid Cancer ◽  
Hormone Therapy ◽  
Differentiated Thyroid Cancer ◽  
Special Treatment ◽  
Malignant Neoplasms ◽  
Urinary System ◽  
Long Term Effects ◽  
Long Term Consequences

Background. Differentiated thyroid cancer (DTC) is the most common endocrine tumour. Its prevalence varies from 1.0% to 2.2% of all malignant neoplasms. The standard strategy of special treatment of DTC consists of surgery, radionuclide therapy and hormone therapy being sequentially applied. Theoretically, each component of the treatment process can cause adverse somatic consequences in future, the study of which can help to prevent and correct them. Purpose – to evaluate possible long-term effects of the treatment of differentiated thyroid cancer in the form of the urinary system (US) pathologies on the basis of follow-up data of long-term observation using sophisticated information technologies. Materials and methods. The study was based on follow-up data of 157 individuals who were undergoing combination treatment of DTC at the Institute clinic from 1993 to 2015, received it in full and underwent regular screening examinations after treatment. The database created for the study contained, as much as possible, digitized arrays of follow-up data of paper case-records on the disease and its consequences in patients with a follow-up period exceeding 1 year after special treatment. The number of logical records of long-term consequences in the generated database was 463 units – one record for one type of long-term consequences of each of 157 patients. Statistical processing of data was carried out in two ways: comparing the incidence of US pathologies before treatment and at a long time after special treatment and identifying factors of statistically significant influence on the occurrence of US pathologies among the treatment peculiarities. WizWhy packages (Data Mining category) and the general purpose software package STATISTICA were used to make hypotheses and test them. Results and discussion. The analysis of the available references has shown that there is only a limited number of papers dealing with the US status of DTC patients. However, a comprehensive analysis of the long-term consequences of treatment of DTC patients revealed a statistically significant increase of US disease cases within the period of 3.75 – 4.8 years after special treatment. It was shown that the total number of US pathologies was 2.04 times higher in comparison with US incidence before the oncet of special treatment. These differences did not depend on age: the median for age of patients before treatment was 51 years, after treatment – 50 years. Additionally, it has been found that patients with or without episodes of postoperative hypothyroidism decompensation with a dose of L-thyroxine not exceeding 2.5 μg/kg need special attention due to the occurrence of urolithiasis. The obtained dependences are quite predictable, since, firstly, it is known that thyroid hormones affect kidney development and physiology, and secondly, the major percent of 131I in radioiodine therapy is excreted with the urine and deposited in the bladder, that can result in a radio-induced carcinogenic effect. Conclusions. Special treatment of DTC increases US pathologies more than twice. The term of post-treatment pathologies is 2.5 (3.75 – 4.8) years. Patients who have episodes of postoperative hypothyroidism during hormone therapy with a dose of L-thyroxine not exceeding 2.5 μg / kg represent the high-risk group.

Sign in / Sign up

Export Citation Format

Share Document